Voyager Therapeutics, Inc.
corporate_fare Company Profile
Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for VYGR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for VYGR spans 10-Q, 8-K, DEF 14A, PRE 14A.
Recent high-impact activity:
- Voyager Q3 Loss Narrows to $24.7M; $132.1M Cash Funds Operations Into Q2 2028
- Voyager Promotes Robin Swartz to President, Taps Her as Next CEO
- Voyager Names Robin Swartz President; CEO Succession Set for Q1 2027
- Voyager's VY1706 Delivers 75% Tau Reduction and Clean Safety in Six-Month Primate Study
- Voyager's Alzheimer's Gene Therapy Shows 75% Tau Reduction, Trial Start H2 2026
Financial Snapshot
Short Interest & Short Volume
4.10 days to coverFINRA reported short interest of 4,377,124 shares in VYGR as of the October 30, 2026 settlement, a 20.3% increase from the prior period — about 4.1 days to cover at its recent average daily volume. On November 19, 2026, 47.2% of VYGR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for VYGR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-10.
Authorized Shares Doubled · Enables Future Capital Flexibility
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →